Is Liquid Cartilage™ available on the NHS?

Liquid Cartilage™ is not available on the NHS. As of mid-2026, NICE has not approved ChondroFiller™ — the injectable collagen scaffold at the heart of the treatment — for routine commissioning, on the grounds that long-term randomised trial data remain insufficient to satisfy NHS evidence thresholds. That is a comment on the maturity of the evidence base, not on the science itself; the device holds CE-marking as a Class III medical implant and is in active clinical use privately across the UK.

No Integrated Care Board in England, including Lincolnshire's, funds this treatment, and no NHS pilot or Individual Funding Request pathway reliably covers it. Patients who ask their GP about hip cartilage repair will typically be directed along the standard NHS route: supervised physiotherapy, oral analgesics or anti-inflammatories, and — when joint damage is advanced — total hip replacement. Regenerative scaffold options sit outside that pathway entirely.

For UK hip patients who want to explore Liquid Cartilage™, private self-funding or insurer pre-authorisation is the only realistic access route.

What Liquid Cartilage™ actually is for the hip

Behind the brand name sits a specific medical device: ChondroFiller™, a CE-marked Class III injectable collagen scaffold derived from murine Type I collagen. When placed into a focal cartilage defect — a contained area of full-thickness damage rather than widespread joint wear — the material self-gels within minutes, bonding to the surrounding tissue to form a stable, three-dimensional matrix.

What happens next is the clinically significant part. The scaffold acts through a process called acellular matrix-induced chondrogenesis: it recruits the patient's own progenitor cells from the synovium and subchondral bone into the defect site, providing a structure within which those cells can mature and support the body's own repair processes. Over time, the scaffold is gradually resorbed as host tissue consolidates in its place.

The hip joint is one of the primary target joints for this treatment, alongside the knee and ankle. Clinically, it is designed for patients with focal articular cartilage damage — the kind caused by hip impingement (FAI), sports trauma, or localised degenerative change — rather than the diffuse cartilage loss associated with established hip osteoarthritis. Suitability depends on defect size, pattern, and the patient's regenerative capacity, all of which are assessed individually.

Two ways the treatment is delivered

ChondroFiller® injection: the outpatient pathway

Delivered as an ultrasound-guided outpatient appointment, the ChondroFiller® injection pathway requires no general anaesthetic and no surgical admission. The collagen scaffold is placed under image guidance directly into the hip joint, where it coats the cartilage surface across the affected area. There is no upper age limit and no defect-size ceiling on this route, which makes it the more broadly accessible of the two options. It suits patients who are not surgical candidates and those whose MRI shows diffuse rather than strictly contained cartilage wear. This is the current service pathway, available as an outpatient injection appointment.

Liquid Cartilage™: the minimally invasive keyhole option

Where MRI confirms a contained focal defect and the patient has adequate regenerative capacity, a day-case minimally invasive procedure under general anaesthetic is an alternative route referenced in clinical literature and available at specialist centres. Scaffold delivery in this context is arthroscopic — precise and targeted at the defined defect site. Candidacy is assessed individually at consultation, based on defect pattern, size, and regenerative profile; it is not the default starting point for most hip patients.

Deciding which route applies

Both pathways use the same acellular collagen scaffold and recruit the body's own progenitor cells; the difference lies in delivery method and patient selection. A private hip consultation — guided primarily by MRI findings — determines which pathway is appropriate for each individual. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without GP referral for that initial assessment.

Who is a suitable candidate with hip cartilage damage

Candidacy is determined by imaging, not by how severe the pain feels. A patient with significant hip discomfort may still not meet the criteria if MRI shows diffuse rather than contained cartilage loss; a well-defined focal defect on scan, by contrast, can indicate suitability even when symptoms seem moderate.

The causes most commonly associated with focal hip cartilage damage include femoroacetabular impingement (FAI), where abnormal bone contact erodes a specific area of cartilage over time; sports injuries or falls that produce acute localised trauma; and early degenerative change before widespread joint involvement has set in. These tend to produce the kind of contained, full-thickness defect pattern that the collagen scaffold is designed to address.

Regenerative capacity — the body's ability to supply the progenitor cells the scaffold needs — is the other key variable, and it is assessed at private consultation alongside detailed MRI review. The typical pre-treatment sequence runs: clinical evaluation covering pain, range of motion, and swelling → imaging (MRI or X-ray) to map the damage pattern → a period of conservative management → private consultation with MRI review → treatment decision. No GP referral is needed to start that process; Lincolnshire Hip accepts hip patients directly, with assessment appointments available in Sleaford and Grantham.

Patients whose MRI shows broader surface wear across the hip joint rather than a single focal lesion may be better served by the outpatient injection pathway — a distinction covered in the previous section.

What the clinical evidence shows for hip outcomes

Published data on ChondroFiller® in hip patients report a mean improvement of approximately 30 points in the modified Harris Hip Score (mHHS) — a validated, hip-specific patient-reported outcome measure that captures pain, function, and mobility. Alongside that, MOCART scores at imaging follow-up range from 70 to 87, indicating substantial cartilage-surface coverage of the treated defect on MRI.

The reported complication rate sits at approximately 0%, and reoperation rates in published series fall between 3% and 8%. Those figures compare favourably with microfracture, which carries reoperation rates of up to 41% and tends to produce fibrocartilage — a mechanically inferior repair tissue — rather than the hyaline-like matrix seen with the collagen scaffold. The defect-size range the scaffold can address also exceeds microfracture's practical ceiling: defects up to 6 cm² have been treated in a single stage, against microfracture's effective limit of roughly 2–4 cm².

Against autologous chondrocyte implantation (ACI) and its matrix-assisted variant (MACI), the scaffold has the advantage of being a one-stage approach; ACI and MACI require two separate procedures and carry complication rates of up to 17% and reoperation rates approaching 37% in some series.

The honest caveat is that large-scale, long-term randomised controlled trial data in hip patients specifically are still limited — and it is that evidence gap, rather than any safety signal, that has led NICE to withhold routine NHS approval.

Accessing this treatment from Lincolnshire

For patients based in Lincolnshire, the practical question is straightforward: no Lincolnshire-based private provider currently offers this specific procedure, and the established route is to travel to a specialist centre, most commonly in London. Professor Paul Lee, who developed both the injectable and surgical ChondroFiller® pathways, has held an Honorary Professorship of Sports Medicine at the University of Lincoln since 2017 — an academic tie that places the clinical work behind this treatment within Lincolnshire's research landscape. That connection does not create a local treatment appointment, but it is the reason this treatment features on a Lincolnshire Hip platform rather than as something entirely remote from the region.

Guide costs and what to budget

The injectable outpatient pathway starts from approximately £3,000. Where the surgical Liquid Cartilage™ option is indicated, the day-case figure is in the region of £9,800. Both are guide figures only and should be confirmed directly with the treating clinic at the time of consultation, as costs can vary with defect complexity and any additional protocol steps. Lincolnshire patients should build travel and accommodation into the overall estimate — a practical consideration for anyone making a same-day or overnight trip to London.

Private insurance

Bupa, Aviva, and WPA are among the insurers that may authorise treatment under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy). Approval is not automatic and depends on the individual policy. Some insurers cover the procedural fee but exclude the implant cost, creating a shortfall the patient meets directly. Written pre-authorisation must be secured before booking — not retrospectively — and patients should check whether their policy covers both elements before proceeding.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment, which is the starting point for establishing whether this pathway is appropriate.